Literature DB >> 19623099

Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.

Pinar Aksoy1, Min Jia Zhu, Krishna R Kalari, Irene Moon, Linda L Pelleymounter, Bruce W Eckloff, Eric D Wieben, Vivien C Yee, Richard M Weinshilboum, Liewei Wang.   

Abstract

BACKGROUND: 5'-Nucleotidases play a critical role in nucleotide pool balance and in the metabolism of nucleoside analogs such as gemcitabine and cytosine arabinoside (AraC). We previously performed an expression array association study with gemcitabine and AraC cytotoxicity using 197 human lymphoblastoid cell lines. One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3. Very little is known with regard to the pharmacogenomics of this family of enzymes.
METHODS: We set out to identify common genetic variation in NT5C3 by resequencing the gene and to determine the effect of that variation on NT5C3 protein function and potential effect on response to cytidine analogs. We identified 61 NT5C3 polymorphisms, 48 of which were novel, by resequencing 240 ethnically defined DNA samples. Functional studies were performed with one nonsynonymous (G847C, Asp283His) and four synonymous cSNPs (T9C, C276T, T306C, and G759A),as well as three combined variants (T276/His283, T276/C306, T276/C9).
RESULTS: The His283 and T276/His283 constructs showed decreased levels of enzyme activity and protein. Substrate kinetic analysis showed no significant differences in Km values between wild type and His283 when cytidine monophosphate, AraCMP, and GemMP were used as substrates. An association study between single nucleotide polymorphisms (SNPs) and NT5C3 expression in the 240 cell lines from which DNA was extracted to resequence NT5C3 identified four SNPs that were significantly associated with NT5C3 expression. Electrophoretic mobility shift assays showed that two of those SNPs, I4(-114) and I6(9), altered DNA-protein binding patterns. These findings suggest that genetic variation in NT5C3 might affect protein function and potentially influence drug response.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19623099      PMCID: PMC2763634          DOI: 10.1097/FPC.0b013e32832c14b8

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  27 in total

1.  Predicting the functional consequences of non-synonymous single nucleotide polymorphisms: structure-based assessment of amino acid variation.

Authors:  D Chasman; R M Adams
Journal:  J Mol Biol       Date:  2001-03-23       Impact factor: 5.469

2.  Accounting for human polymorphisms predicted to affect protein function.

Authors:  Pauline C Ng; Steven Henikoff
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

Review 3.  Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity.

Authors:  Richard Weinshilboum; Liewei Wang
Journal:  Clin Pharmacol Ther       Date:  2004-04       Impact factor: 6.875

4.  Molecular basis of pyrimidine 5'-nucleotidase deficiency caused by 3 newly identified missense mutations (c.187T>C, c.469G>C and c.740T>C) and a tabulation of known mutations.

Authors:  Laurent R Chiarelli; Simone M Morera; Alessandro Galizzi; Elisa Fermo; Alberto Zanella; Giovanna Valentini
Journal:  Blood Cells Mol Dis       Date:  2008 May-Jun       Impact factor: 3.039

5.  Glutathione s-transferase p1: gene sequence variation and functional genomic studies.

Authors:  Ann M Moyer; Oreste E Salavaggione; Tse-Yu Wu; Irene Moon; Bruce W Eckloff; Michelle A T Hildebrandt; Daniel J Schaid; Eric D Wieben; Richard M Weinshilboum
Journal:  Cancer Res       Date:  2008-06-15       Impact factor: 12.701

6.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

7.  Studies on human erythrocyte nucleotide metabolism. II. Nonspherocytic hemolytic anemia, high red cell ATP, and ribosephosphate pyrophosphokinase (RPK, E.C.2.7.6.1) deficiency.

Authors:  W N Valentine; H M Anderson; D E Paglia; E R Jaffé; P N Konrad; S R Harris
Journal:  Blood       Date:  1972-05       Impact factor: 22.113

8.  Purification, microsequencing, and immunolocalization of p36, a new interferon-alpha-induced protein that is associated with human lupus inclusions.

Authors:  S A Rich; M Bose; P Tempst; U H Rudofsky
Journal:  J Biol Chem       Date:  1996-01-12       Impact factor: 5.157

9.  Genetic basis of hemolytic anemia caused by pyrimidine 5' nucleotidase deficiency.

Authors:  A M Marinaki; E Escuredo; J A Duley; H A Simmonds; A Amici; V Naponelli; G Magni; M Seip; I Ben-Bassat; E H Harley; S L Thein; D C Rees
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

Review 10.  Hereditary erythrocyte pyrimidine 5'-nucleotidase deficiency: a biochemical, genetic and clinical overview.

Authors:  Laurent R Chiarelli; Elisa Fermo; Alberto Zanella; Giovanna Valentini
Journal:  Hematology       Date:  2006-02       Impact factor: 2.269

View more
  12 in total

1.  Inhibition of alpha interferon (IFN-α)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-α.

Authors:  Junli Hao; Wensong Jin; Xinghui Li; Saifeng Wang; Xiaojun Zhang; Hongxia Fan; Changfei Li; Lizhao Chen; Bin Gao; Guangze Liu; Songdong Meng
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

2.  Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

Authors:  Naveen L Pereira; Pinar Aksoy; Irene Moon; Yi Peng; Margaret M Redfield; John C Burnett; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum
Journal:  J Mol Cell Cardiol       Date:  2010-08-06       Impact factor: 5.000

Review 3.  Impact of the 1000 genomes project on the next wave of pharmacogenomic discovery.

Authors:  Wei Zhang; M Eileen Dolan
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

4.  Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.

Authors:  Liang Li; Daniel J Schaid; Brooke L Fridley; Krishna R Kalari; Gregory D Jenkins; Ryan P Abo; Anthony Batzler; Irene Moon; Linda Pelleymounter; Bruce W Eckloff; Eric D Wieben; Zhifu Sun; Ping Yang; Liewei Wang
Journal:  Pharmacogenet Genomics       Date:  2012-02       Impact factor: 2.089

5.  Gene expression profiling of peripheral blood mononuclear cells in the setting of peripheral arterial disease.

Authors:  Rizwan Masud; Khader Shameer; Aparna Dhar; Keyue Ding; Iftikhar J Kullo
Journal:  J Clin Bioinforma       Date:  2012-03-12

6.  Proteomics of muscle chronological ageing in post-menopausal women.

Authors:  Marine Gueugneau; Cécile Coudy-Gandilhon; Ophélie Gourbeyre; Christophe Chambon; Lydie Combaret; Cécile Polge; Daniel Taillandier; Didier Attaix; Bertrand Friguet; Andrea B Maier; Gillian Butler-Browne; Daniel Béchet
Journal:  BMC Genomics       Date:  2014-12-23       Impact factor: 3.969

7.  Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study.

Authors:  Nour Abdo; Menghang Xia; Chad C Brown; Oksana Kosyk; Ruili Huang; Srilatha Sakamuru; Yi-Hui Zhou; John R Jack; Paul Gallins; Kai Xia; Yun Li; Weihsueh A Chiu; Alison A Motsinger-Reif; Christopher P Austin; Raymond R Tice; Ivan Rusyn; Fred A Wright
Journal:  Environ Health Perspect       Date:  2015-01-13       Impact factor: 9.031

8.  Assessment of mTOR-Dependent Translational Regulation of Interferon Stimulated Genes.

Authors:  Mark Livingstone; Kristina Sikström; Philippe A Robert; Gilles Uzé; Ola Larsson; Sandra Pellegrini
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

9.  Characterization of the Gene Expression Patterns in the Murine Liver Following Intramuscular Administration of Baculovirus.

Authors:  Mitsuhiro Iyori; Ryohei Ogawa; Talha Bin Emran; Shuta Tanbo; Shigeto Yoshida
Journal:  Gene Expr       Date:  2020-10-28

10.  Cellular Metabolomics Profiles Associated With Drug Chemosensitivity in AML.

Authors:  Bradley Stockard; Neha Bhise; Miyoung Shin; Joy Guingab-Cagmat; Timothy J Garrett; Stanley Pounds; Jatinder K Lamba
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.